Synthesized of 2,7 dihydroxyxanthone from xanthone and antimalarial activities

To cite this article: Amanatie et al 2018 IOP Conf. Ser.: Mater. Sci. Eng. 333 012061

View the article online for updates and enhancements.
Synthesized of 2,7 dihydroxyxanthone from xanthone and antimalarial activities

Amanatie1*, Jumina2, Mustofa3, Hanafi4

1 Department of chemistry, Faculty of Mathematics and Natural Sciences, Yogyakarta State University, Yogyakarta. 55281 Indonesia.
2 Department of Chemistry, Faculty of Mathematics and Natural Sciences, Gadjah Mada University, Yogyakarta. 55281 Indonesia.
3 Faculty of Medicine, Gadjah Mada University, Yogyakarta, 55281 Indonesia.
4 P3K LIPI Serpong Tangerang, 15314 Indonesia.

E-mail: amanatie@uny.ac.id.

Abstract: The purpose of the research is to synthesize 2,7- di-hydroxyxanthone compounds from xanthone and to evaluate antiplasmodial against activities. The synthesize of 2,7-di-hydroxyxanthone compounds worked with chromatography methods including Thin Layer Chromatography (TLC), Vacuum Liquid Chromatography (VLC). A compound structures were determined based on the spectroscopic evidences including, Infrared (IR), one dimension (1-D) and two dimension (2-D) Nuclear Magnetic Resonance (NMR) spectra and comparison the spectroscopy data with related data from references. The biological properties of compounds are evaluated towards antimalarial against activity. The result of the product was obtained as white solid in 63.49% yield. The IR spectrum showed the absorption at 3433 cm⁻¹ Which was reinforced with a sharp attack at 1087 cm⁻¹ indicating the stretching of OH, while the stretching of aromatic C=C appeared at 1620 cm⁻¹. The 1H-NMR (500MHz, and DMSO–d6) spectrum showed that the aryl protons appeared in the region of δ12.98 ppm. In this region, there were 2 singlet at δH 12.98 ppm (1H, 2-OH) and (1H, 7-OH) and shows the presence of two OH groups. Based on spectroscopy analyses, it could be started that the reaction of 2.7 di-aminoxanthone with NaNO₂/HCl and H₃PO₄ produced 2,7- di-hydroxyxanthone. In vitro antimalarial assay of the product synthesized 2,7 di-hydroxyxanthones against. Falciparum strain of 3D7 showed that the IC₅₀ values of 2,7-di-hydroxy xanthone, were 0.31 μg/mL, respectively.

1 Introduction

Malaria is global health problem in developing countries. The efforts to eliminate this disease have been doing in many ways. However, the expected results is still not given. Evenmore, malaria becomes one of threatening disease in the world. This is indicated by the increase of malaria incidence especially in the endemic area. There are several problems against malaria. The main problems is the presence of malaria vectors (mosquito) which are resistant to insecticide and the resistant malaria parasites (such as
Plasmodium falciparum) to anti-malaria drugs (such as chloroquine). The parasites are widely spread almost in all endemic area at whole over the world. Therefore, such anti-malaria drugs are not effective and sensitive anymore. These reasons lead the researchers to find the new anti-malaria drugs. One of strategies is based on the development of active compounds obtained from medicinal plants, which are traditionally used by people to cure malaria [1]. From 400 of Garcinia plants, it was found that xanthone was the major component, beside terpenoid, benzophenone and biflavonoid. 2-hydroxy xanthone, 2,7 dihydroxyxanthone had the potential biological activities. The 2,7-di-hydroxyxanthone as antimalaria agent has not been reported.

Figure 1. Structure xanthone

The efforts to find the new antimalarial drugs could be done in several ways, such as: a) synthesis of 2-hydroxyxanthone compound which could inhibit the specific metabolism of parasite, b) isolation of active compounds of natural products which are traditionally employed to cure malaria, and c) synthesis of analog compound of anti-malaria drugs, [2]. This research was initialized by isolating and identifying the xanthones from the root of G. Dulcis as well as performing the anti-malaria assay [3]. However, the yield obtained was very low. Several xanthone derivatives were reported to display antimalaria activities [4]. Xanthones could selectively inhibit the growth of P. falciparum in culture. Study on anti-malaria activity of xanthone derivatives showed that there was correlation between the structure and the anti-malaria activity (IC50). Preliminary study on IC50 value (the inhibition value of P.falciparum growth) with semi empirical method of PM3 showed that the anti-malaria activity was correlated with the electronic properties of the substituents [5]. Xanthone and its derivatives were commonly obtained from isolation of natural products. Isolation of xanthone has been conducted from the leave [6] and bark [7] of Garcinia dulcis. [8] has obtained new xanthone derivatives of 7-O-methyl garcinon-E from G. cowa with IC50 of 1.50-3.00 µg/mL. Other xanthone derivatives of 1,3,7-tri oxygenated and prenylated xanthone have been isolated from Calophyllum caledonicum [9]. The originality of this research could be seen as the synthesized 2,7 dihydroxy xanthones have been conducted. The in vitro antiplasmodium assay of the product synthesized 2,7-dihydroxyxanthones to P. falciparum strain 3D7 has not been reported. This research was synthesized of 2,7 dihydroxyxanthone and analyzed of the product synthesized 2,7dihydroxyxanthones using UV-Vis, IR, 1H-NMR, 13C-NMR spectrometers and Test in vitro antimalaria assay of the synthesized 2,7 dihydroxyxanthones against P.falciparum. This research was conducted with the main aims of synthesizing the 2,7-dihydroxyxanthones and performing the in vitro antimalaria assay of the 2,7 di-hydroxyxanthone. The specific aims were 1) To synthesized the 2,7dihydroxy xanthone from 2,7-diaminoxanthone; 2) To analyzed the product synthesized 2,7-dihydroxyxanthones using spectroscopy method (FTIR, 1H-NMR, 13C-NMR, spectrometer); and 3) To conduct new antimalarial activity of the 2,7-di-hydroxyxanthone.
2. Experimental

2.1. Material chemical compounds:
2-Hydroxy xanthone, Hydrogen Chloride (HCl), Natrium Nitride (NaNO₂), phosphoric acid, ethanol-aquades. HEPES buffer, P. falciparum, Gentamicin sulfate, NaHCO₃, serum and red blood cells, Giemsa dyes.

2.2. General procedure:
Spektra of Infra Red (IR): Perkin-Elmer Spectrum One FT-IR spectrophotometers. Spektra of ¹H and ¹³C NMR: spektrofotometer JEOL LTD ECP400, operated at 400 MHz (¹H) and 100.53 MHz (¹³C), use aceton-d₆ as solvent and TMS as internal standard. Separation and purification used Thin Layer Chromatography (TLC), Vacuum Liquid Chromatography (VLC).

2.3. Procedure of the synthesized of 2,7-di-hydroxyxanthone
The 2,7diaminoxantone compound of 0.01 gram (0.00005 mol) was introduced into the 3-neck flask, suspended in Hydrogen Chloride (HCl) and added 10 mL of Natrium Nitride (NaNO₂) 2.8 M at 5 °C until the solution changed entirely to yellow. The mixture was stirred at 5°C for 30 minutes and then added 15 ml of 1 M Hydrogen Chloride (HCl) solution and be cooled. The resulting mixture was stirred at 5°C for 5 hours, acidified with phosphoric acid. The product is recrystallized with ethanol-aquades. The obtained product was analyzed by Infrared (IR) spectrometer, one dimension (1-D) and two dimension (2-D) Nuclear Magnetic Resonance (NMR) spectra.

2.4. Procedure Testing the effect of antiplasmodium in vitro
Testing the effect of antiplasmodium in vitro is required P. falciparum culture. The cultures used were 3D7, bred by the Trager and Jensen method modified by Waruyanti, [10], [11] by candle jar with RPMI 1640, HEPES buffer, Gentamicin sulfate, NaHCO₃, serum and red blood cells. The breeding is carried out in a sticked glass candle and incubated glass exchanger in the incubator at 37°C. The medium is replaced periodically every 24 hours. The P. falciparum stage required for this test was a ring shaped young trophozoite obtained by synchronization in a 5% w/v sorbitol solution. The anti-plasmodium effect test of the 2,7-di-hydroxyxanton compound is performed in a microbial well. Into the micro well plate which has been given the test compound with various concentrations, given 50 μl of P. falciparum suspension. Incubate in incubator at 37°C for 24 hours. The results were evaluated by making the dosage form with Giemsa dyes. The number of living schizons accounted for 200 asexual parasites, used as a criterion for the effects of antiplasmodium. From the observation results obtained IC₅₀ value indicates that the test compound has activity inhibiting the growth of P. falciparum in vitro. Then continued data analysis with probit analysis.
3 Result and Discussion
3.1 The strategy is via Fries rearrangement of diaryl ester derivatives (Figure 2) [12].

![Figure 2. Synthesized of xanthone via benzophenone route](image)

3.2 Synthesized of 2-hydroxyxanthone

The synthesized 2-hydroxyxanthone from monoaminoxanthone was reacted with NaNO₂, HCl, and H₃PO₄ (Figure 3).

![Figure 3. Synthesized of 2-hydroxyxanthone](image)

3.3 Analyzed of 2-hydroxyxanthone

2-Hydroxy xanthone was obtained by reacting 2-aminoxanthone with NaNO₂ to produce diazonium salt. Then, hydrolyzed of the salt produce 2-hydroxyxanthone. The product was obtained as white solid in 69.80% yield. The IR spectrum showed the absorption at 3433 cm⁻¹ indicating the stretching of OH, while the stretching of aromatic C=C appeared at 1620 cm⁻¹. The ¹H-NMR spectrum showed that the aryl protons appeared in the region of δ 6.97 - 7.78 ppm. In this region, there were 4 doublet at δ 6.97 (H, J = 8.3 Hz), 7.26 (H, J=8.3 Hz), 7.37 (H, J=8.3 Hz), and 7.78 (2H, J=23Hz) ppm as well as one doublet of doublet peak at δ 7.50 ppm (2H, dd, J and 8.3 Hz). One singlet peak from hydroxyl proton appeared at δ 12.53 ppm. Identification of the product using ¹³C-NMR showed aryl carbons at δ 106, 110, 117, 137 and
155ppm. The peak at δ 113, 116, 118, 135, 136, 161 dan δ 179.2 from the carbonyl group while the peak at δ 175 ppm was the peak for the carbon (C4) next to hydroxyl group. Based on spectroscopy analyses, it could be stated that the reaction of 2-aminoxanthone with NaNO2/HCl and H3PO4 produced 2-hydroxyxanthone. The reaction mechanism was presented on Figure 4.

3.4. Synthesized 2,7-di-hydroxyxanthone
The product was obtained as white solid in 63.49% yield. The IR spectrum showed the absorption at 3433 cm⁻¹ which was reinforced with a sharp attack at 1087cm⁻¹ indicating the stretching of OH, while the stretching of aromatic C=C appeared at 1620 cm⁻¹. The ¹H-NMR (500MHz, and DMSO –d6) spectrum showed that the aryl protons appeared in the region of δ12.98 ppm. In this region, there were 2singlet at δ9.12.98 ppm (1H, 2-OH) and (1H, 7-OH), shows the presence of two OH groups. An aromatic proton appears in the intermediate region of δ 7.30-7.69ppm ie 7.69 for H₅ and H₆ (2H.d.J =2.4Hz), 7.43 for H₃ and H₆ (2H, dd, J = 2.4 and 8.2Hz) and 7.30 ppm for H₄ and H₆ (2H.d,j= 8.2Hz).

Identification of the product using ¹³C-NMR( 125MHz, CDCl₃) Shows the presence of three peaks of the CH group aryl carbons at 119.56 (2C, C₄ and C₅, 11.8.74 ( 2C, C₃ and C₆), and 117.41ppm(2C, C₁ and C₈). 3 peaks of quaternary carbon groups appear on the region 151.44 (2C. C₉ and C₁₂), 148.58 (2C, C₂ and C₇) and 122.45 ppm (2C, C₁₀ and C₁₁), 1 peak of carbonyl group C=O at 179.22 ppm at C₁₃.

3.5. Anti-malarial Activity Test
Malaria is a disease caused by the infection of protozoa from the genus of *Plasmodium*. There are 4 species of *Plasmodium* which could cause malaria. They are *P. falciparum*, *P. vivax*, *P. malariae*, and *P. ovale* ([13], [14], [15], [16], [17]). Among them, *P. Falciparum* is the most responsible to the malaria caused death. Moreover, patients could be infected by more than one species of *Plasmodium*, for example *P. falciparum* and *P. vivax* in subtropical area, *P. falciparum* and *P. malariae* in tropical country in Africa. Results of survey showed that there are 15 million case of malaria, where 70 million citizens live in the malaria endemic area. In Jawa and Bali, the case of malaria increased from 0.12 per 1,000 citizens to 0.81 per 1,000 citizens [18].90% in Africa, 4% in South East Asia, 4% in Mediterania and 2% in other
area)[19]. Resistance of malaria parasite to standard anti-malaria drugs of chloroquin was found in South America (Columbia and Venezuela) in 1960 [20], and followed in Thailand in 1961. The resistance of *P. falciparum* to chloroquin was reported in Kalimantan in 1974 and spread in all provinces in 1996 [21]. The situation is getting worse due to the case of resistance of *P. falciparum* to drugs of sulfadoxin-pirimetamine in 10 provinces and kina in 5 provinces in Indonesia [22]. Another resistance to meflokuin has also been reported. In fact the drug has not been utilized in Indonesia [23]. Chloroquin as the first line anti-malaria drug in the world has important role in controlling and medication of malaria. The other important factors are pharmacological and transmission factors[21]. In addition, the genetic recombination on sexual stadium between gametocyte and different strain in the mosquitoes could lead the genetic mutation [24]. Chloroquin has been considered to have activity in inhibiting the production of hemozoin on the vacuole of malaria parasites. However, the resistant mechanism of *P. falciparum* to chloroquine has not been known yet [25]. There were several hypotheses regarding the resistant mechanism, such as the change in metabolism pathway, thus the anti-malaria drug which enter the *Plasmodium* could not be metabolized properly. Characteristic of resistant parasites to chloroquin is the fast efflux, while that of sensitive parasites is it could survive against radioisotope-label-drug for longer period [26]. The resistance has forced the researchers to find new anti-malarial drugs to substitute the non sensitive anti-malaria drugs against *P. falciparum*.

The study give to synthesized 2.7-dihydroxyxanthone and biological activity as well as new antimalarial activity with IC50=0.31µg/mL.

4. Conclusions

According to results and discussion, it could be concluded that: 1) 2,7-di-Hydroxy xanthone which theoretically displayed antimalarial activity. 2) Reaction of 2,7-di-aminoxanthone with NaNO2, HCl and H3PO4 produced 2,7- di-hydroxyxanthone in 63.49 % yield. 3) *In vitro* antiplasmodial assay of the product synthesized 2.7-dihydroxyxanthone against *P.falciparum* strain of 3D7 showed that the IC50 values were 0 31µg/mL, respectively.

REFERENCES

[1] Mustofa 2009 *Professor Speech Inaguration* (Yogyakarta: Gadjah Mada University)
[2] Sholikah EN 2010 *Dissertation Doctoral of Program, Faculty of Medicine* (Yogyakarta: Gadjah Mada University)
[3] Amanatie, Jumina M, Hanafi M 2009 *Development of new compound xanton derivatives from Garcinia dulcis root as antiplasmodium* (Yogyakarta: Research Institute of Yogyakarta State University)
[4] Likhitwitayawuid K, Chanmahasathien W, Ruangrungsi N, Kungkrai J 2000 *Plana Med.* 64 70-77
[5] Likhitwitayawuid K, Ruangrungsi N, Kungkrai J 2001 *Planta Med.* 64 70-72
[6] Kosela S, Hu IH, Rahmatia T, Hanafi M, Sim K.Y 2000 *J. Nat. Prod.* 63 406-407
[7] Hanafi M, Soemiati A, Kosela S, Leslie J. H 2004 *Proc. Int. Conf. UGM*
[8] Likhitwitayawuid K, Chanmahasathien W, Ruangrungsi N, Kungkrai J 2000 *Plana Med.* 64 70-72
[9] Hay AE, Helesbeux J J, Duval O, Labaied, M, Grellier P, and Richomme P 2004 *Life Sci.* 75 3077-85
[10] Wijayanti MA, Supargiyono, Mustofa, Sholikhah EN, Jumina, Tahir I., Hadanu R 2007 *Proc. Int. Conf. Chem Sci. (ICCS-2007) 237-242*
[11] Neetu T, Shiv V S, Chottes L J, Gaurav V, Anirban P, Vineeta S 2015 *Asian J. Phar. Clin. Res.* **8**(2) 47-50
[12] Naidoo J M 2009 *Novel Methodology for The Synthesis of Xanthones Thesis* (Johannesburg: University Withwatersrand)
[13] Siswadono, Sukardjo B 2000 *Principles of Drug Design* (Surabaya: Erlangga University Press)
[14] Ramya TNC, Suroliya N, Surolia A 2002 *Curr. Sci.* **83**(7) 818-25
[15] Zein U 2005 *Recent Handling of Malaria Falciparum Repository* (Medan: University of Sumatra Utara)
[16] Ashley E, McGready R, Proux S, Nosten F 2006 *Malaria, Travel Med. Infect. Dis.* 159-173
[17] Daily JP 2006 *J. Clin. Pharmacol.* **46** 1487-97
[18] Syamgudin, Dewi R M, Hernita 2004 *Airlangga Phar. Mag.* **4**(3) 101-104
[19] WHO 2013 *Malaria* http://www.who.int/mediacentre/factsheets/fs094/en/ accessed on March 23, 2013
[20] Krogstad DJ 1996 *Epidemiol. Rev.* **18**(1) 77-89
[21] Zein U 2005 *Recent Handling of Malaria Falciparum Repository* (Medan: University of Sumatra Utara)
[22] Achmad M.F, Sutanto I 2003 *Indonesian Med. Mag.* **53**(2) 72
[23] Emiliana T, Tutti S, Renny M, Arbani P R, Harijani AM 1993 Cermin *Dunia Kedokteran* 82
[24] Black RH, Canfield CJ, Clide DF, Peters W, Wernsdorfer WH 1968 *Chemotherapy of Malaria 2nd Ed* (Geneva: WHO) **136** 357-361
[25] Zaranz B, Jaso, A, Lima LM, Aldana I, Monge A, Maurel S, Sauvain M 2006 *J. Pharm. Sci.* **42**(3) 357-361
[26] Ramya TNC, Suroliya N, Surolia A 2002 *Curr. Sci.*, **83**(7) 818-825